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motility, proliferation and invasion, and a block of apoptosis, contribut-
ing to cancer development and progression. 
Geﬁtinib (ZD 1839, Iressa™, AstraZeneca, UK) and erlotinib (OSI 
774, Tarceva™, Genentech, US) are orally active, selective EGFR 
Tyrosine Kinase Inhibitors (EGFR-TKIs) that demonstrated anti-tumor 
activity in a variety of human cancer cell lines overexpressing EGFR. 
The encouraging results observed in phase II studies and the survival 
improvement observed in phase III trials in certain subgroup of patients 
indicate that these drugs are particularly effective in individuals with 
particular clinical or biological characteristics. Several clinical features 
were found associated with increased response or survival to EGFR-
TKIs, including never smoking history, female gender, adenocarcinoma 
histology and Asian ethnicity. During the last three years, biological 
predictors for EGFR-TKI sensitivity have been discovered. In 2004, 
three groups have shown that mutations in the TK domain of EGFR 
were associated with response of NSCLC to geﬁtinib or erlotinib. 
These mutations were somatic and more frequently observed in patients 
with clinical features known to be associated with TKI sensitivity, such 
as female gender, adenocarcinoma histology, Asiatic ethnicity and 
never smoking history. Many types of mutations have been reported, 
but so far only four drug-sensitive mutations have been validated. The 
most common EGFR drug-sensitive mutations are exon 19 deletions 
and exon 21 L858R substitution, together accounting for about 85% of 
all EGFR mutations in NSCLC. Other less frequent EGFR mutations 
include substitutions in exon 18 (G719A/C) and 21 (L861Q). Several 
other EGFR gene mutations have been described but their role is not 
clear, and it is not possible to exclude that some of them are artefacts. 
Although several retrospective and prospective studies showed that 
patients with EGFR mutations, particularly individuals harbouring 
exon 19 deletion, respond to TKIs, the impact on survival is unclear 
because of the possible prognostic rather than predictive value of such 
mutations. Survival analysis of the largest trials with TKIs showed no 
survival beneﬁt for patients harbouring EGFR mutations receiving a 
TKI, suggesting a possible prognostic impact. In the randomized pla-
cebo-controlled trial comparing erlotinib to placebo (BR21), presence 
of EGFR mutations did not predict for a survival beneﬁt from the TKI 
therapy, even if mutation analysis was restricted to patients harbour-
ing the most frequent EGFR mutations (exon 19 deletion and exon 
21 L858R substitution). Since the ﬁrst reports, clearly emerged that a 
signiﬁcant fraction of patients with EGFR mutations (12%-84%) do 
not respond to TKIs, suggesting that other mechanisms are involved 
in TKI sensitivity. Four studies evaluated EGFR gene copy number 
by Fluorescence In Situ Hybridization (FISH). In the Italian study, 
individuals with EGFR high polysomy or gene ampliﬁcation (deﬁned 
as EGFR FISH positive) had a signiﬁcantly higher response rate, and a 
signiﬁcantly longer time to progression and survival than patients with 
no EGFR gene gain (deﬁned EGFR FISH negative). In the randomized 
placebo-controlled phase III study of erlotinib versus placebo, EGFR 
FISH positive patients treated with erlotinib had higher response rate 
and longer survival than EGFR FISH positive treated with placebo 
(HR 0.44, p=0.008), whereas there was no advantage determined by 
the drug in FISH negative patients. The randomized placebo-controlled 
phase III study of geﬁtinib versus placebo (ISEL) conﬁrmed the better 
outcome in terms of response rate and survival for EGFR FISH positive 
patients treated with geﬁtinib than EGFR FISH positive treated with 
placebo, with no survival difference in EGFR FISH negative irrespec-
tive of the treatment. In the SWOG S0126 trial, where patients with 
bronchiolo alveolar carcinoma (BAC) were treated with geﬁtinib 500 
mg/day, Hirsch et al. observed longer survival for EGFR FISH positive 
patients over those who had no gene gain (HR 2.02, p=0.042). More 
recently, the ONCOBELL trial, a prospective phase II study evaluating 
response rate in EGFR FISH positive or never smoker patients treated 
with geﬁtinib conﬁrmed that EGFR FISH testing is useful for patient 
selection. In this study, response rate was 68% in EGFR FISH positive 
and no response was observed in never smokers negative for EGFR 
FISH and mutation. Response and survival improvement observed 
in EGFR FISH positive patients indicate that TKI therapy should be 
offered to patients with such biological characteristic. Because gain 
in copy number of the EGFR gene was associated with survival, and 
because FISH is readily available clinical test, the EGFR FISH analysis 
represents an ideal test for selecting patients candidate to TKI therapy.
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Targeted therapies directed against epidermal growth factor recep-
tor (EGFR) are effective in a subset of non-small cell lung cancer 
(NSCLC) patients, however the survival advantage in unselected popu-
lations is relatively modest (1, 2). Numerous tissue and serum based 
markers have been proposed as predictors of survival and response 
beneﬁt from EGFR inhibitors. EGFR gene copy number and muta-
tion analyses are now being explored in prospective clinical studies in 
enriched populations. These assays are very promising, however costly 
and not widely available. In contrast, protein expression studies by 
immunohistochemistry are routinely performed in many laboratories 
for selection of breast cancer patients to hormonal therapy and HER2 
inhibitor trastuzumab. 
The value of EGFR protein expression as a predictor of sensitivity to 
EGFR inhibitors is debated. Depending on the analyzed cohort, stain-
ing protocol and cut-off point, EGFR protein positivity is observed in 
approximately 60% - 90% of patients. Analyses from phase II clinical 
studies with geﬁtinib concluded that EGFR protein expression is not 
associated with increased response rates or prolonged survival (3). 
Phase III clinical studies with erlotinib versus placebo in combination 
with chemotherapy followed by maintenance erlotinib/placebo did not 
show any association of outcome and EGFR protein expression (4, 5). 
It may be concluded from these studies that concurrent treatment with 
EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy is equally 
ineffective in EGFR positive (EGFR+) and EGFR negative (EGFR-
) patients. Results of NSCLC monotherapy trials with geﬁtinib or 
erlotinib indicated that approximately 8 - 13% of EGFR+ as compared 
to 2-5% of EGFR- chemotherapy-pretreated patients respond to these 
agents. Moreover, some survival improvement was observed in EGFR+ 
patients in prospective monotherapy studies (BR.21 trial - hazard ratio 
[HR]: 0.68, 95% conﬁdence interval [CI]: 0.49 - 0.95, p=0.02; ISEL 
trial - HR: 0.77, 95% CI: 0.56 - 1.08, p=0.126) whereas no survival ad-
vantage was shown in EGFR- patients (6, 7). Detailed analysis of cut-
off points to deﬁne EGFR protein positivity based on BR.21 and ISEL 
trials with erlotinib and geﬁtinib, respectively, indicated that low cut-
off points (i.e. 10% of cells with positive staining of any intensity) were 
better discriminators of survival advantage than higher cut-off points 
(8, 9). Other single-arm studies indicated that EGFR protein expression 
is associated with outcome independently from other biologic features 
(10, 11). In a combined cohort of geﬁtinib treated patients, EGFR+ pa-
tients for both gene copy number and protein expression had a median 
survival of 21 months, patients with single positive test - 11 months and 
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patients with both negative tests - 6 months. These data suggest that 
EGFR protein expression, alone or with other markers, may be useful 
predictor of sensitivity to EGFR TKIs and that EGFR negative patients 
by immunohistochemistry are unlikely to beneﬁt from these drugs. The 
value of EGFR protein expression for patient selection to the ﬁrst-line 
and adjuvant treatments is currently tested in several clinical studies in 
enriched populations (e.g. RADIANT adjuvant trial with erlotinib).
Activated EGFR (p-EGFR) as well as several downstream signaling 
proteins (p-Akt, p-MAPK, p-STAT3) and epithelial-to-mesenchymal 
transition markers (E-cadherin, vimentin) were studied in relation to 
sensitivity to EGFR TKIs in vitro as well as in clinical samples. P-Akt 
positivity was associated with improved response rate and time to pro-
gression in one retrospective study (12), but molecular analysis of the 
ISEL trial with geﬁtinib did not conﬁrm this ﬁnding (6). At present, we 
have insufﬁcient data to use these markers as predictors of sensitivity to 
EGFR inhibitors in practice.
Data on protein expression and the outcome of patients treated with 
anti-EGFR monoclonal antibodies are scarce. Most of the studies with 
cetuximab enrolled NSCLC patients with EGFR protein-positive tu-
mors, and therefore it is impossible to assess the value of EGFR status 
on study outcome. 
Tumor heterogeneity, differences between surgical versus bronchos-
copy specimens or primary versus metastatic tumors may account for 
variations that should be recognized when using immunohistochemistry 
for patient selection. Different antibodies and grading systems should 
also be taken into account. Counting of positive tumor cells and grad-
ing of staining intensity may be a subject of interobserver variability, 
which should be evaluated. Automated scoring systems are available, 
but comparison studies with light microscopy and conventional scoring 
are needed prior to their wide-spread use. 
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Introduction
Early detection of central type lesions, especially intraepithelial stage, 
is a challenge for bronchoscopists. Last decade has witnessed several 
advances in both technical and clinical aspects of bronchology. These 
advances have led to better diagnostic yield from bronchoscopy. 
Fiberoptic bronchoscope has been replaced by videoendoscope, so 
bronchoscopists can capture more detailed images of the bronchus. 
Inhaled carcinogens may cause cumulative genetic damage to the entire 
bronchial surface resulting in genetic disorder. The multicentric nature 
of central type lung cancer may be the result of ﬁeld cancerization. 
This theory also supports the concept of multistep carcinogenesis: lung 
cancer developing through a series of morphological changes from dys-
plasia to carcinoma in situ and then invasive cancer. The Lung Cancer 
Screening Study at Johns Hopkins found that moderate dysplasia in 
sputum may result in a 10% future incidence of lung cancer and 40% of 
severe dysplasia results in future cancer development (1). The detection 
of dysplastic lesions are also encouraged because they are regarded 
as precancerous lesions. However, dysplasias are generally a few cell 
layers thick and are detected only by chance. Autoﬂuorescence bron-
choscopy (AFB) has widely spread since early 1990’s. Several studies 
have shown that AFB improved the sensitivity of cancer and dysplastic 
lesions of the airway, especially those in intraepithelial stage (2-10). 
Recently, videoendoscopy-based autoﬂuorescence systems have come 
into clinical use (9,10). Synchronous dual images with white light and 
AFB with better resolution than that of ﬁberscopy-based AFB could be 
obtained. (10)
Patients
There is as yet no universally accepted indication as to who should 
undergo AFB. Indications need to be established based on the consider-
ation of beneﬁt and risk of this procedure.
Usually, cases for AFB are classiﬁed into 4 groups as described below.
Patients with known or suspected lung cancer who were scheduled for 
bronchoscopy as a part of standard examination.
Patients with abnormal sputum cytology ﬁndings (moderate atypia or 
worse) with a normal chest radiograph.
Patients after curative surgery of stage I lung cancer who were sched-
uled for bronchoscopy as a part of follow up.
